An exploratory phase III prospective open-label clinical study on monthly OCT monitoring of the effects of Ozurdex for macular oedema related to retinal vascular diseases.

Trial Profile

An exploratory phase III prospective open-label clinical study on monthly OCT monitoring of the effects of Ozurdex for macular oedema related to retinal vascular diseases.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms OCTOME
  • Sponsors Allergan
  • Most Recent Events

    • 25 Jul 2012 Planned end date changed from 9 Jun 2012 to 12 Apr 2012 as reported by United Kingdom Clinical Research Network.
    • 25 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 06 May 2012 United Kingdom Clinical Research Network reports accrual to date changed from 96% to 100%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top